M-receptor Antagonist Versus Ureteral Stent Placement in the Deployment of Ureteral Access Sheath (UAS) During Flexible Ureteroscopy (fURS): A Prospective Cohort Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027728

Enrollment

Unknown

Registered

2019-11-24

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urolithiasis

Interventions

Tamsulosin Group:2 wks preoperation oral intake tamsulosin 0.4mg qn

Tolterodine Group:2 wks preoperation oral intake tolterodine 2mg bid

Prestenting Group:2 wks preoperation ureterla stent placement at affected side under local anesthesia

Control Group:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with proximal or renal urolithiasis receiving flexible ureteroscopy (fURS) treatment; 2. A documented sterile urine culture before the procedure; 3. Patients more than 18-year old; 4. Ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of affected-side ureteral stent prior to scheduled procedure; 2. Planned concurrent bilateral fURS procedures; 3. Patients currently taking alpha-blockers or M-blockers or have been placed ureteral stenting in the same side prior to scheduled procedure; 4. Pregnant or lactating women; 5. Uncontrolled urinary tract infection (UTI) or uncorrected coagulopathy; 6. Patients who cannot stop their blood thinners, and/or non-steroidal anti-inflammatory medications 5-7 days prior to the procedure; 7. Patients allergic to tamsulosin or tolterodine; 8. Patients with gravis myasthenia; 9. Patients with risk of gastric retention; 10. Patients with severe ulcerative colitis or toxic megacolon; 11. Patients with urinary retention; 12. Patients with uncontrolled narrow-angle glaucoma; 13. Patients with high risk cardiovascular disease; 14. Patients with renal or hepatic dysfunction; 15. patients using CYP3A4 inhibitors.

Design outcomes

Primary

Measure	Time frame
The success rate of deployment of ureteral access sheath.;Ureteral injuries;	—

Secondary

Measure	Time frame
Complications morbidity;Adverse effects morbidity;	—

Contacts

Public ContactGang Chen

The First Affiliated Hospital of Chongqing Medical University

chengang2308@163.com+86 13668039053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026